

AMENDMENTS

IN THE CLAIMS

1. (Currently Amended) An oral ~~dosage form~~ **formulation** comprising:
~~a formulation that, upon exposure to an aqueous environment, forms a network within the formulation and an outer surface, wherein the formulation comprises:~~
a drug;
~~about 30—90 weight percent of sucrose acetate isobutyrate (SAIB) as a high viscosity liquid carrier material (HVLCM);~~
a network former;
a rheology modifier selected from the group consisting of isopropyl myristate (IPM), ethyl oleate, ~~triethyl citrate~~, dimethyl phthalate, benzyl benzoate, and a caprylic/capric triglyceride; and
~~a solvent, wherein said formulation provides for release of the drug over a prolonged period of time of at least an hour and is resistant to drug extraction using ethanol.~~

2.-79. (Cancelled)

80. (Currently Amended) The oral dosage form **formulation** of claim 1, wherein the formulation comprises from **about 1 to about 8.6** ~~1—8.6~~ weight percent of the network former.

81. (Currently Amended) The oral dosage form **formulation** of claim 80 **claim 1**, wherein the network former comprises a cellulose acetate butyrate (CAB).

82. (Currently Amended) The oral dosage form **formulation** of claim [[1]] **81**, wherein the **CAB has a butyryl content range from 17 to 38 weight percent, an acetyl content range from 13 to 30 weight percent, and a hydroxyl content range from 0.8 to 1.7 weight percent** ~~drug is selected from the group consisting of opioids, CNS depressants, and stimulants.~~

83. (Currently Amended) The oral dosage form **formulation** of claim 1, wherein the formulation comprises from **about 20** [[—]] **to about 50** weight percent of the solvent.

84. (Currently Amended) The oral dosage form formulation of claim 83, wherein the solvent is selected from the group consisting of ethyl lactate (EL), triacetin, dimethyl sulfoxide (DMSO), propylene carbonate, N-methylpyrrolidone (NMP), ethyl alcohol, benzyl alcohol, glycofurool, alpha-tocoperol, isopropyl alcohol, diethyl phthalate, polyethylene glycol 400 (PEG 400), triethyl citrate, benzyl benzoate, and a caprylic/capric triglyceride.

85. (New) The oral formulation of claim 1, wherein the rheology modifier is IPM.

86. (New) The oral formulation of claim 1, wherein the solvent is triacetin.

87. (New) The oral formulation of claim 1, wherein the network former is selected from the group consisting of a cellulose acetate, cellulose acetate butyrate, cellulose acetate phthalate, a carbohydrate polymer, an organic ester of a polymer, a hydrogel, silicon dioxide, and an ion exchange resin.

88. (New) The oral formulation of claim 1, wherein the formulation comprises:
from about 0.01 to about 75 weight percent of the network former;
from about 1 to about 75 weight percent of the rheology modifier; and
from about 0.01 to about 75 weight percent of the solvent.

89. (New) The oral formulation of claim 1, wherein the drug is selected from the group consisting of an opioid, a central nervous system (CNS) depressant and a stimulant.

90. (New) The oral formulation of claim 89, wherein the drug is an opioid.

91. (New) The oral formulation of claim 89, wherein the drug is oxycodone, hydrocodone, oxymorphone or hydromorphone.

92. (New) The oral formulation of claim 89, wherein the drug is oxycodone.

93. (New) The oral formulation of claim 89, wherein the drug is a stimulant.

94. (New) The oral formulation of claim 93, wherein the drug is dextroamphetamine or methylphenidate.

95. (New) An oral dosage form comprising the formulation of claim 1, wherein the formulation is contained in a capsule.

96. (New) The oral dosage form of claim 95, wherein the capsule is a gelatin capsule.

97. (New) An oral formulation comprising:

a drug;
sucrose acetate isobutyrate (SAIB);
a network former;
a rheology modifier; and
a solvent in which the network former is soluble.

98. (New) The oral formulation of claim 97, wherein the network former comprises a cellulose acetate butyrate or cellulose acetate phthalate.

99. (New) The oral formulation of claim 97, wherein the network former is cellulose acetate butyrate (CAB).

100. (New) The oral formulation of claim 99, wherein the CAB has a butyryl content range from 17 to 38 weight percent, an acetyl content range from 13 to 30 weight percent, and a hydroxyl content range from 0.8 to 1.7 weight percent.

101. (New) The oral formulation of claim 97, wherein the rheology modifier is selected from the group consisting of isopropyl myristate (IPM), ethyl oleate, triethyl citrate, dimethyl phthalate, benzyl benzoate, and a caprylic/capric triglyceride.

102. (New) The oral formulation of claim 97, wherein the rheology modifier is IPM.

103. (New) The oral formulation of claim 97, wherein the solvent is selected from the group consisting of ethyl lactate (EL), triacetin, dimethyl sulfoxide (DMSO), propylene carbonate, N-methylpyrrolidone (NMP), ethyl alcohol, benzyl alcohol, glycofurool, alpha-tocoperol, isopropyl alcohol, diethyl phthalate, polyethylene glycol 400 (PEG 400), triethyl citrate, benzyl benzoate, and a caprylic/capric triglyceride.

104. (New) The oral formulation of claim 97, wherein the solvent is triacetin.

105. (New) The oral formulation of claim 97, wherein the drug is selected from the group consisting of an opioid, a central nervous system (CNS) depressant and a stimulant.

106. (New) The oral formulation of claim 97, wherein the drug is an opioid.

107. (New) The oral formulation of claim 106, wherein the drug is oxycodone, hydrocodone, oxymorphone or hydromorphone.

108. (New) The oral formulation of claim 106, wherein the drug is oxycodone.

109. (New) The oral formulation of claim 97, wherein the drug is a stimulant.

110. (New) The oral formulation of claim 97, wherein the drug is dextroamphetamine or methylphenidate.

111. (New) An oral dosage form comprising the formulation of claim 97, wherein the formulation is contained in a capsule.

112. (New) The oral dosage form of claim 111, wherein the capsule is a gelatin capsule.

113. (New) An oral formulation comprising:

- a drug;
- sucrose acetate isobutyrate (SAIB);
- a network former;
- a rheology modifier selected from the group consisting of isopropyl myristate (IPM), ethyl oleate, dimethyl phthalate, benzyl benzoate, and a caprylic/capric triglyceride; and
- a solvent in which the network former is soluble.

114. (New) The oral formulation of claim 113, wherein the network former comprises a cellulose acetate butyrate or cellulose acetate phthalate.

115. (New) The oral formulation of claim 113, wherein the network former comprises cellulose acetate butyrate (CAB).

116. (New) The oral formulation of claim 113, wherein the CAB has a butyryl content range from 17 to 38 weight percent, an acetyl content range from 13 to 30 weight percent, and a hydroxyl content range from 0.8 to 1.7 weight percent.

117. (New) The oral formulation of claim 113, wherein the rheology modifier is IPM.

118. (New) The oral formulation of claim 113, wherein the solvent is triacetin.

119. (New) The oral formulation of claim 113, wherein the drug is selected from the group consisting of an opioid, a central nervous system (CNS) depressant and a stimulant.

120. (New) The oral formulation of claim 113, wherein the drug is an opioid.

121. (New) The oral formulation of claim 120, wherein the drug is oxycodone, hydrocodone, oxymorphone or hydromorphone.

122. (New) The oral formulation of claim 120, wherein the drug is oxycodone.

123. (New) The oral formulation of claim 113, wherein the drug is a CNS stimulant.

124. (New) The oral formulation of claim 113, wherein the drug is dextroamphetamine or methylphenidate.

125. (New) An oral dosage form comprising the formulation of claim 113, wherein the formulation is contained in a capsule.

126. (New) The oral dosage form of claim 125, wherein the capsule is a gelatin capsule.